BPNT1

Across TCGA pan-cancer cohorts, BPNT1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BPNT1 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher BPNT1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BPNT1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where BPNT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.660	0.436	<.001	72	view →
CCRCC	DFS	Median	II,III,IV	0.887	0.283	.012	27	view →
LUAD	OS	Median	All	0.906	0.774	.017	3	view →
LSCC	OS	Quartile	All	0.737	0.910	.025	3	view →
HNSC	DFS	Median	III,IV	0.937	1.000	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BPNT1–PDAC (OS)

Open the PDAC breakdown →